FDA Approves Pig Liver Clinical Trial for Acute Liver Failure
- WASHINGTON (AP) — The Food and Drug Management has approved the first clinical trial in the U.S.to test the use of genetically engineered pig livers to support patients...
- The trial is a collaborative effort between Egenesis, a Massachusetts-based biotechnology company, and Organox, a British medical technology firm. Egenesis announced Tuesday, April 15, 2025, that the pig...
- Many are ineligible for liver transplants or face long waits due to a shortage of donor organs.
FDA Approves Trial Using Genetically Modified Pig Livers for Acute Liver Failure
Table of Contents
- FDA Approves Trial Using Genetically Modified Pig Livers for Acute Liver Failure
- FDA Approves Trial Using Genetically Modified Pig Livers for Acute Liver Failure: Your Questions Answered
- What is the FDA approving?
- What is the goal of this trial?
- How does this procedure offer hope to patients?
- Who is involved in this clinical trial?
- How will the pig livers be used?
- What are the key advantages of this method?
- How many people are affected by acute liver failure each year?
- Why is there a need for option liver support?
- how does the liver’s ability to regenerate play a role?
- What genetic modifications have the pigs undergone?
- What technology is Organox using?
- How many patients will participate in the clinical trial?
- What is xenotransplantation?
- How is this trial a milestone in xenotransplantation?
- What are the potential outcomes if this trial is successful?
- What where the results of previous tests on pig livers?
- Where can I find more details about this clinical trial?
- Could this technology be expanded to help with other organ failures in the future?
WASHINGTON (AP) — The Food and Drug Management has approved the first clinical trial in the U.S.to test the use of genetically engineered pig livers to support patients experiencing acute liver failure. The experimental procedure aims to provide a temporary bridge, allowing patients’ own livers time to regenerate and recover.
Collaboration drives Xenotransplantation Innovation
The trial is a collaborative effort between Egenesis, a Massachusetts-based biotechnology company, and Organox, a British medical technology firm. Egenesis announced Tuesday, April 15, 2025, that the pig livers will function externally, filtering the patient’s blood rather than being transplanted into the body.
Addressing Critical Need for Liver Support
Approximately 35,000 patients in the U.S. receive treatment for acute liver failure annually. Many are ineligible for liver transplants or face long waits due to a shortage of donor organs. This research offers a potential solution to sustain patients during this critical period.
Liver’s Regenerative capacity Key to Approach
Researchers are leveraging the liver’s unique ability to regenerate. By using the pig liver to perform liver functions temporarily, the patient’s own liver may have the opportunity to recover naturally. Previous tests on deceased individuals showed that pig livers could perform several human liver functions for two to three days.
Genetic Modifications Enhance Compatibility
Mike Curtis, CEO of Egenesis, stated that the pigs have undergone genetic modifications to make thier organs more compatible with humans, reducing the risk of rejection. The clinical trial will involve up to 20 patients in intensive care who are not eligible for transplants.
Organox Technology Plays Crucial Role
The trial will utilize technology developed by Organox, previously used to preserve donor livers before transplantation. This technology will now be adapted to circulate a patient’s blood through the external pig liver, providing temporary support.
Milestone in Xenotransplantation
This clinical trial represents a significant step forward in xenotransplantation,the transplantation of organs from one species to another. It offers a potential avenue for addressing the critical shortage of human organ donors.If successful, this approach could save lives and offer new hope to patients worldwide suffering from liver failure.
FDA Approves Trial Using Genetically Modified Pig Livers for Acute Liver Failure: Your Questions Answered
What is the FDA approving?
the Food and Drug Management (FDA) has approved the first clinical trial in the U.S. to test the use of genetically engineered pig livers to support patients experiencing acute liver failure.
What is the goal of this trial?
The experimental procedure aims to provide a temporary “bridge” for patients, allowing their own livers time to regenerate and recover.
How does this procedure offer hope to patients?
This new approach may sustain patients who are ineligible for liver transplants or face long waits due to donor organ shortages.
Who is involved in this clinical trial?
The trial is a collaborative effort between:
Egenesis: A Massachusetts-based biotechnology company.
Organox: A British medical technology firm.
How will the pig livers be used?
The pig livers will function externally, filtering the patients’ blood. They will not be transplanted into the patient’s body.
What are the key advantages of this method?
The advantages are that the patient gets temporary support from a pig liver, allowing their native liver time to heal and regenerate.
How many people are affected by acute liver failure each year?
approximately 35,000 patients in the U.S. recieve treatment for acute liver failure annually.
Why is there a need for option liver support?
Many patients are ineligible for liver transplants, or they face lengthy waiting times due to a shortage of human donor organs. This new approach could offer a solution to sustain patients during this critical period.
how does the liver’s ability to regenerate play a role?
Researchers are leveraging the liver’s unique ability to regenerate. by temporarily using the pig liver to perform liver functions, the patient’s own liver may have the opportunity to recover naturally.
What genetic modifications have the pigs undergone?
The pigs have undergone genetic modifications to make their organs more compatible with humans, reducing the risk of rejection.
What technology is Organox using?
Organox is adapting technology previously used to preserve donor livers before transplantation. This technology will now circulate a patient’s blood through the external pig liver, providing temporary support.
How many patients will participate in the clinical trial?
The clinical trial will involve up to 20 patients in intensive care who are not eligible for transplants.
What is xenotransplantation?
Xenotransplantation is the transplantation of organs from one species to another.
How is this trial a milestone in xenotransplantation?
This clinical trial represents a notable step forward in xenotransplantation. It offers a potential avenue for addressing the critical shortage of human organ donors.
What are the potential outcomes if this trial is successful?
If successful, this approach could:
Save lives
Offer new hope to patients worldwide suffering from liver failure
What where the results of previous tests on pig livers?
Previous tests on deceased individuals showed that pig livers could perform several human liver functions for two to three days.
Where can I find more details about this clinical trial?
Further details about the trial,including participating hospitals and eligibility criteria (if released) may be found by searching clinical trial databases or by contacting the involved companies (Egenesis and Organox). Please note that the release of such details are not included in the source article.
Could this technology be expanded to help with other organ failures in the future?
While the article focuses on acute liver failure, the advancements and technologies from xenotransplantation could potentially led to new approaches to address shortages of other organs in the future.This is speculative information, not explicitly mentioned from the source.
Summary of Key aspects
Here is a summary of the key aspects of this ground-breaking trial:
| Feature | Description |
|——————————-|——————————————————————————-|
| Focus | Acute liver failure |
| Treatment | External filtering using genetically modified pig livers |
| Goal | Temporary support to allow the patient’s liver to regenerate |
| Collaboration | Egenesis & Organox |
| Patients Affected (U.S.) | Approximately 35,000 annually |
| Pig Modification | Genetic alterations for enhanced human compatibility |
| Organs Used | Pig livers are external, used to circulate blood |
| Technology | Organox technology adapted from donor liver preservation |
| Potential Impact | Addresses the organ shortage and offers hope |